#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Diet interventions are well-established strategies to reduce body weight and improve glucose metabolism , however no evidence exists about the effects of periodic fasting on NAFLD .
2-1	14-18	Diet	organization|event[3]	new|new[3]	coref|coref	10-8[74_3]|10-8[74_3]
2-2	19-32	interventions	event[3]	new[3]	_	_
2-3	33-36	are	_	_	_	_
2-4	37-53	well-established	_	_	_	_
2-5	54-64	strategies	abstract	new	_	_
2-6	65-67	to	_	_	_	_
2-7	68-74	reduce	_	_	_	_
2-8	75-79	body	object|abstract[6]	new|new[6]	coref|coref|coref|coref	11-16[0_6]|18-3[129_0]|11-16[0_6]|18-3[129_0]
2-9	80-86	weight	abstract[6]	new[6]	_	_
2-10	87-90	and	_	_	_	_
2-11	91-98	improve	abstract|abstract	new|new	coref|none|none|none|coref|none|none|none	22-19[161_0]|2-11|2-11[0_278]|33-18|22-19[161_0]|2-11|2-11[0_278]|33-18
2-12	99-106	glucose	substance|abstract[8]	new|new[8]	_	_
2-13	107-117	metabolism	abstract[8]	new[8]	_	_
2-14	118-119	,	_	_	_	_
2-15	120-127	however	_	_	_	_
2-16	128-130	no	abstract[9]	new[9]	coref	18-7[130_9]
2-17	131-139	evidence	abstract[9]	new[9]	_	_
2-18	140-146	exists	_	_	_	_
2-19	147-152	about	_	_	_	_
2-20	153-156	the	abstract[10]	new[10]	_	_
2-21	157-164	effects	abstract[10]	new[10]	_	_
2-22	165-167	of	abstract[10]	new[10]	_	_
2-23	168-176	periodic	abstract[10]|abstract[11]	new[10]|new[11]	coref	3-12[15_11]
2-24	177-184	fasting	abstract[10]|abstract[11]	new[10]|new[11]	_	_
2-25	185-187	on	abstract[10]|abstract[11]	new[10]|new[11]	_	_
2-26	188-193	NAFLD	abstract[10]|abstract[11]|substance	new[10]|new[11]|new	coref	9-5
2-27	194-195	.	_	_	_	_

#Text=This study is the first to show the beneficial effects of periodic fasting on fatty liver .
3-1	196-200	This	abstract[13]	new[13]	coref	4-4[19_13]
3-2	201-206	study	abstract[13]	new[13]	_	_
3-3	207-209	is	_	_	_	_
3-4	210-213	the	_	_	_	_
3-5	214-219	first	_	_	_	_
3-6	220-222	to	_	_	_	_
3-7	223-227	show	_	_	_	_
3-8	228-231	the	abstract[14]	new[14]	_	_
3-9	232-242	beneficial	abstract[14]	new[14]	_	_
3-10	243-250	effects	abstract[14]	new[14]	_	_
3-11	251-253	of	abstract[14]	new[14]	_	_
3-12	254-262	periodic	abstract[14]|abstract[15]	new[14]|giv[15]	coref	4-29[0_15]
3-13	263-270	fasting	abstract[14]|abstract[15]	new[14]|giv[15]	_	_
3-14	271-273	on	abstract[14]|abstract[15]	new[14]|giv[15]	_	_
3-15	274-279	fatty	abstract[14]|abstract[15]|object[16]	new[14]|giv[15]|new[16]	coref	4-16[23_16]
3-16	280-285	liver	abstract[14]|abstract[15]|object[16]	new[14]|giv[15]|new[16]	_	_
3-17	286-287	.	_	_	_	_

#Text=The results of our study supported the hypothesis that FLI , a surrogate parameter of fatty liver , significantly decreases in individuals with and without T2DM after a fasting intervention of at least 6 days .
4-1	288-291	The	abstract[17]	new[17]	coref	7-1[43_17]
4-2	292-299	results	abstract[17]	new[17]	_	_
4-3	300-302	of	abstract[17]	new[17]	_	_
4-4	303-306	our	abstract[17]|person|abstract[19]	new[17]|acc|giv[19]	coref|ana|coref|ana	5-3[0_19]|7-1|5-3[0_19]|7-1
4-5	307-312	study	abstract[17]|abstract[19]	new[17]|giv[19]	_	_
4-6	313-322	supported	_	_	_	_
4-7	323-326	the	abstract[20]	new[20]	coref	17-4[125_20]
4-8	327-337	hypothesis	abstract[20]	new[20]	_	_
4-9	338-342	that	_	_	_	_
4-10	343-346	FLI	abstract	new	appos	4-12[22_0]
4-11	347-348	,	_	_	_	_
4-12	349-350	a	abstract[22]	giv[22]	coref	8-15[0_22]
4-13	351-360	surrogate	abstract[22]	giv[22]	_	_
4-14	361-370	parameter	abstract[22]	giv[22]	_	_
4-15	371-373	of	abstract[22]	giv[22]	_	_
4-16	374-379	fatty	abstract[22]|object[23]	giv[22]|giv[23]	coref	6-7[0_23]
4-17	380-385	liver	abstract[22]|object[23]	giv[22]|giv[23]	_	_
4-18	386-387	,	_	_	_	_
4-19	388-401	significantly	_	_	_	_
4-20	402-411	decreases	_	_	_	_
4-21	412-414	in	_	_	_	_
4-22	415-426	individuals	person	new	_	_
4-23	427-431	with	_	_	_	_
4-24	432-435	and	_	_	_	_
4-25	436-443	without	_	_	_	_
4-26	444-448	T2DM	event	new	coref	26-20
4-27	449-454	after	_	_	_	_
4-28	455-456	a	event[27]	new[27]	coref	11-25[0_27]
4-29	457-464	fasting	abstract|event[27]	giv|new[27]	coref	5-13
4-30	465-477	intervention	event[27]	new[27]	_	_
4-31	478-480	of	event[27]	new[27]	_	_
4-32	481-483	at	event[27]|time[28]	new[27]|new[28]	_	_
4-33	484-489	least	event[27]|time[28]	new[27]|new[28]	_	_
4-34	490-491	6	event[27]|time[28]	new[27]|new[28]	_	_
4-35	492-496	days	event[27]|time[28]	new[27]|new[28]	_	_
4-36	497-498	.	_	_	_	_

#Text=The prospective study design according to a standardized protocol with a well-established fasting technique and a close clinical monitoring was a strength of this study .
5-1	499-502	The	abstract[30]	new[30]	coref	5-21[35_30]
5-2	503-514	prospective	abstract[30]	new[30]	_	_
5-3	515-520	study	abstract|abstract[30]	giv|new[30]	coref	5-24[36_0]
5-4	521-527	design	abstract[30]	new[30]	_	_
5-5	528-537	according	abstract[30]	new[30]	_	_
5-6	538-540	to	abstract[30]	new[30]	_	_
5-7	541-542	a	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-8	543-555	standardized	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-9	556-564	protocol	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-10	565-569	with	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-11	570-571	a	abstract[30]|abstract[31]|abstract[33]	new[30]|new[31]|new[33]	_	_
5-12	572-588	well-established	abstract[30]|abstract[31]|abstract[33]	new[30]|new[31]|new[33]	_	_
5-13	589-596	fasting	abstract[30]|abstract[31]|abstract|abstract[33]	new[30]|new[31]|giv|new[33]	coref	12-3[88_0]
5-14	597-606	technique	abstract[30]|abstract[31]|abstract[33]	new[30]|new[31]|new[33]	_	_
5-15	607-610	and	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-16	611-612	a	abstract[30]|abstract[31]|abstract[34]	new[30]|new[31]|new[34]	_	_
5-17	613-618	close	abstract[30]|abstract[31]|abstract[34]	new[30]|new[31]|new[34]	_	_
5-18	619-627	clinical	abstract[30]|abstract[31]|abstract[34]	new[30]|new[31]|new[34]	_	_
5-19	628-638	monitoring	abstract[30]|abstract[31]|abstract[34]	new[30]|new[31]|new[34]	_	_
5-20	639-642	was	_	_	_	_
5-21	643-644	a	abstract[35]	giv[35]	_	_
5-22	645-653	strength	abstract[35]	giv[35]	_	_
5-23	654-656	of	abstract[35]	giv[35]	_	_
5-24	657-661	this	abstract[35]|abstract[36]	giv[35]|giv[36]	coref	16-8[122_36]
5-25	662-667	study	abstract[35]|abstract[36]	giv[35]|giv[36]	_	_
5-26	668-669	.	_	_	_	_

#Text=Weight reduction and improvement of fatty liver indicators are known to be interrelated .
6-1	670-676	Weight	person|abstract[38]	new|new[38]	coref|coref	7-5[44_38]|7-5[44_38]
6-2	677-686	reduction	abstract[38]	new[38]	_	_
6-3	687-690	and	_	_	_	_
6-4	691-702	improvement	abstract[39]	new[39]	_	_
6-5	703-705	of	abstract[39]	new[39]	_	_
6-6	706-711	fatty	abstract[39]|abstract[41]	new[39]|new[41]	_	_
6-7	712-717	liver	abstract[39]|object|abstract[41]	new[39]|giv|new[41]	coref	7-15[48_0]
6-8	718-728	indicators	abstract[39]|abstract[41]	new[39]|new[41]	_	_
6-9	729-732	are	_	_	_	_
6-10	733-738	known	_	_	_	_
6-11	739-741	to	_	_	_	_
6-12	742-744	be	_	_	_	_
6-13	745-757	interrelated	_	_	_	_
6-14	758-759	.	_	_	_	_

#Text=Our results indicate that even a modest reduction of BMI improved surrogate markers of fatty liver .
7-1	760-763	Our	person|abstract[43]	giv|giv[43]	ana|ana	17-1|17-1
7-2	764-771	results	abstract[43]	giv[43]	_	_
7-3	772-780	indicate	_	_	_	_
7-4	781-785	that	_	_	_	_
7-5	786-790	even	abstract[44]	giv[44]	_	_
7-6	791-792	a	abstract[44]	giv[44]	_	_
7-7	793-799	modest	abstract[44]	giv[44]	_	_
7-8	800-809	reduction	abstract[44]	giv[44]	_	_
7-9	810-812	of	abstract[44]	giv[44]	_	_
7-10	813-816	BMI	abstract[44]|abstract	giv[44]|new	coref	8-21
7-11	817-825	improved	abstract[47]	new[47]	_	_
7-12	826-835	surrogate	abstract|abstract[47]	new|new[47]	_	_
7-13	836-843	markers	abstract[47]	new[47]	_	_
7-14	844-846	of	abstract[47]	new[47]	_	_
7-15	847-852	fatty	abstract[47]|object[48]	new[47]|giv[48]	coref	27-13[0_48]
7-16	853-858	liver	abstract[47]|object[48]	new[47]|giv[48]	_	_
7-17	859-860	.	_	_	_	_

#Text=Indeed , in nearly half of the subjects in the highest risk category ( FLI > 60 ) , a BMI reduction of less than 5 % was sufficient to induce a shift to a lower risk category .
8-1	861-867	Indeed	_	_	_	_
8-2	868-869	,	_	_	_	_
8-3	870-872	in	_	_	_	_
8-4	873-879	nearly	quantity[49]	new[49]	_	_
8-5	880-884	half	quantity[49]	new[49]	_	_
8-6	885-887	of	quantity[49]	new[49]	_	_
8-7	888-891	the	quantity[49]|person[50]	new[49]|new[50]	coref	15-14[105_50]
8-8	892-900	subjects	quantity[49]|person[50]	new[49]|new[50]	_	_
8-9	901-903	in	quantity[49]|person[50]	new[49]|new[50]	_	_
8-10	904-907	the	quantity[49]|person[50]|abstract[52]	new[49]|new[50]|new[52]	_	_
8-11	908-915	highest	quantity[49]|person[50]|abstract[52]	new[49]|new[50]|new[52]	_	_
8-12	916-920	risk	quantity[49]|person[50]|abstract|abstract[52]	new[49]|new[50]|new|new[52]	coref	8-37
8-13	921-929	category	quantity[49]|person[50]|abstract[52]	new[49]|new[50]|new[52]	_	_
8-14	930-931	(	_	_	_	_
8-15	932-935	FLI	abstract	giv	coref	28-20
8-16	936-937	>	_	_	_	_
8-17	938-940	60	quantity	new	_	_
8-18	941-942	)	_	_	_	_
8-19	943-944	,	_	_	_	_
8-20	945-946	a	abstract[56]	new[56]	coref	19-16[141_56]
8-21	947-950	BMI	organization|abstract[56]	giv|new[56]	_	_
8-22	951-960	reduction	abstract[56]	new[56]	_	_
8-23	961-963	of	abstract[56]	new[56]	_	_
8-24	964-968	less	abstract[56]|quantity[57]	new[56]|new[57]	_	_
8-25	969-973	than	abstract[56]|quantity[57]	new[56]|new[57]	_	_
8-26	974-975	5	abstract[56]|quantity[57]	new[56]|new[57]	_	_
8-27	976-977	%	abstract[56]|quantity[57]	new[56]|new[57]	_	_
8-28	978-981	was	_	_	_	_
8-29	982-992	sufficient	_	_	_	_
8-30	993-995	to	_	_	_	_
8-31	996-1002	induce	_	_	_	_
8-32	1003-1004	a	event[58]	new[58]	_	_
8-33	1005-1010	shift	event[58]	new[58]	_	_
8-34	1011-1013	to	_	_	_	_
8-35	1014-1015	a	abstract[60]	new[60]	_	_
8-36	1016-1021	lower	abstract[60]	new[60]	_	_
8-37	1022-1026	risk	abstract|abstract[60]	giv|new[60]	_	_
8-38	1027-1035	category	abstract[60]	new[60]	_	_
8-39	1036-1037	.	_	_	_	_

#Text=In most patients , NAFLD is associated with features of metabolic syndrome , central obesity , elevated blood pressure , dyslipidemia , hyperglycemia , and insulin resistance .
9-1	1038-1040	In	_	_	_	_
9-2	1041-1045	most	person[61]	new[61]	coref	28-26[220_61]
9-3	1046-1054	patients	person[61]	new[61]	_	_
9-4	1055-1056	,	_	_	_	_
9-5	1057-1062	NAFLD	substance	giv	coref	18-19
9-6	1063-1065	is	_	_	_	_
9-7	1066-1076	associated	_	_	_	_
9-8	1077-1081	with	_	_	_	_
9-9	1082-1090	features	abstract[63]	new[63]	_	_
9-10	1091-1093	of	abstract[63]	new[63]	_	_
9-11	1094-1103	metabolic	abstract[63]|person|abstract[65]	new[63]|new|new[65]	coref|coref	20-2|20-2
9-12	1104-1112	syndrome	abstract[63]|abstract[65]	new[63]|new[65]	_	_
9-13	1113-1114	,	abstract[63]	new[63]	_	_
9-14	1115-1122	central	abstract[63]|abstract[66]	new[63]|new[66]	coref	26-14[0_66]
9-15	1123-1130	obesity	abstract[63]|abstract[66]	new[63]|new[66]	_	_
9-16	1131-1132	,	abstract[63]	new[63]	_	_
9-17	1133-1141	elevated	abstract[63]|abstract[67]	new[63]|new[67]	_	_
9-18	1142-1147	blood	abstract[63]|abstract[67]	new[63]|new[67]	_	_
9-19	1148-1156	pressure	abstract[63]|abstract[67]	new[63]|new[67]	_	_
9-20	1157-1158	,	abstract[63]	new[63]	_	_
9-21	1159-1171	dyslipidemia	abstract[63]|abstract	new[63]|new	_	_
9-22	1172-1173	,	abstract[63]	new[63]	_	_
9-23	1174-1187	hyperglycemia	abstract[63]|abstract	new[63]|new	_	_
9-24	1188-1189	,	abstract[63]	new[63]	_	_
9-25	1190-1193	and	abstract[63]	new[63]	_	_
9-26	1194-1201	insulin	abstract[63]|event|abstract[71]	new[63]|new|new[71]	coref|coref|coref|coref	26-16|26-16[199_71]|26-16|26-16[199_71]
9-27	1202-1212	resistance	abstract[63]|abstract[71]	new[63]|new[71]	_	_
9-28	1213-1214	.	_	_	_	_

#Text=Although these pathologies can be addressed by lifestyle interventions , in daily life the adherence to the necessary lifestyle changes is poor , resulting in suboptimal outcomes .
10-1	1215-1223	Although	_	_	_	_
10-2	1224-1229	these	abstract[72]	new[72]	_	_
10-3	1230-1241	pathologies	abstract[72]	new[72]	_	_
10-4	1242-1245	can	_	_	_	_
10-5	1246-1248	be	_	_	_	_
10-6	1249-1258	addressed	_	_	_	_
10-7	1259-1261	by	_	_	_	_
10-8	1262-1271	lifestyle	abstract|event[74]	new|giv[74]	coref|coref	10-19|10-19
10-9	1272-1285	interventions	event[74]	giv[74]	_	_
10-10	1286-1287	,	_	_	_	_
10-11	1288-1290	in	_	_	_	_
10-12	1291-1296	daily	abstract[75]	new[75]	coref	11-24[87_75]
10-13	1297-1301	life	abstract[75]	new[75]	_	_
10-14	1302-1305	the	event[76]	new[76]	coref	15-43[116_76]
10-15	1306-1315	adherence	event[76]	new[76]	_	_
10-16	1316-1318	to	event[76]	new[76]	_	_
10-17	1319-1322	the	event[76]|abstract[78]	new[76]|new[78]	_	_
10-18	1323-1332	necessary	event[76]|abstract[78]	new[76]|new[78]	_	_
10-19	1333-1342	lifestyle	event[76]|abstract|abstract[78]	new[76]|giv|new[78]	coref	15-43
10-20	1343-1350	changes	event[76]|abstract[78]	new[76]|new[78]	_	_
10-21	1351-1353	is	_	_	_	_
10-22	1354-1358	poor	_	_	_	_
10-23	1359-1360	,	_	_	_	_
10-24	1361-1370	resulting	_	_	_	_
10-25	1371-1373	in	_	_	_	_
10-26	1374-1384	suboptimal	abstract[79]	new[79]	coref	15-39[114_79]
10-27	1385-1393	outcomes	abstract[79]	new[79]	_	_
10-28	1394-1395	.	_	_	_	_

#Text=In contrast , in pragmatic programs there is a greater benefit in a more substantial weight loss , particularly at early stages of the intervention period .
11-1	1396-1398	In	_	_	_	_
11-2	1399-1407	contrast	abstract	new	coref	15-2
11-3	1408-1409	,	_	_	_	_
11-4	1410-1412	in	_	_	_	_
11-5	1413-1422	pragmatic	abstract[81]	new[81]	_	_
11-6	1423-1431	programs	abstract[81]	new[81]	_	_
11-7	1432-1437	there	_	_	_	_
11-8	1438-1440	is	_	_	_	_
11-9	1441-1442	a	abstract[82]	new[82]	_	_
11-10	1443-1450	greater	abstract[82]	new[82]	_	_
11-11	1451-1458	benefit	abstract[82]	new[82]	_	_
11-12	1459-1461	in	abstract[82]	new[82]	_	_
11-13	1462-1463	a	abstract[82]|abstract[84]	new[82]|new[84]	coref	22-6[0_84]
11-14	1464-1468	more	abstract[82]|abstract[84]	new[82]|new[84]	_	_
11-15	1469-1480	substantial	abstract[82]|abstract[84]	new[82]|new[84]	_	_
11-16	1481-1487	weight	abstract[82]|abstract|abstract[84]	new[82]|giv|new[84]	coref	12-8
11-17	1488-1492	loss	abstract[82]|abstract[84]	new[82]|new[84]	_	_
11-18	1493-1494	,	_	_	_	_
11-19	1495-1507	particularly	abstract[85]	new[85]	_	_
11-20	1508-1510	at	abstract[85]	new[85]	_	_
11-21	1511-1516	early	abstract[85]	new[85]	_	_
11-22	1517-1523	stages	abstract[85]	new[85]	_	_
11-23	1524-1526	of	abstract[85]	new[85]	_	_
11-24	1527-1530	the	abstract[85]|abstract[87]	new[85]|giv[87]	_	_
11-25	1531-1543	intervention	abstract[85]|event|abstract[87]	new[85]|giv|giv[87]	_	_
11-26	1544-1550	period	abstract[85]|abstract[87]	new[85]|giv[87]	_	_
11-27	1551-1552	.	_	_	_	_

#Text=Hence , periodic fasting can significantly reduce weight , and this effect can be maintained over time .
12-1	1553-1558	Hence	_	_	_	_
12-2	1559-1560	,	_	_	_	_
12-3	1561-1569	periodic	abstract[88]	giv[88]	coref	13-10[0_88]
12-4	1570-1577	fasting	abstract[88]	giv[88]	_	_
12-5	1578-1581	can	_	_	_	_
12-6	1582-1595	significantly	_	_	_	_
12-7	1596-1602	reduce	_	_	_	_
12-8	1603-1609	weight	abstract	giv	coref	19-10
12-9	1610-1611	,	_	_	_	_
12-10	1612-1615	and	_	_	_	_
12-11	1616-1620	this	abstract[90]	new[90]	_	_
12-12	1621-1627	effect	abstract[90]	new[90]	_	_
12-13	1628-1631	can	_	_	_	_
12-14	1632-1634	be	_	_	_	_
12-15	1635-1645	maintained	_	_	_	_
12-16	1646-1650	over	_	_	_	_
12-17	1651-1655	time	_	_	_	_
12-18	1656-1657	.	_	_	_	_

#Text=There are several concerns about the adverse effects of fasting .
13-1	1658-1663	There	_	_	_	_
13-2	1664-1667	are	_	_	_	_
13-3	1668-1675	several	abstract[91]	new[91]	_	_
13-4	1676-1684	concerns	abstract[91]	new[91]	_	_
13-5	1685-1690	about	abstract[91]	new[91]	_	_
13-6	1691-1694	the	abstract[91]|abstract[92]	new[91]|new[92]	coref	15-37[113_92]
13-7	1695-1702	adverse	abstract[91]|abstract[92]	new[91]|new[92]	_	_
13-8	1703-1710	effects	abstract[91]|abstract[92]	new[91]|new[92]	_	_
13-9	1711-1713	of	abstract[91]|abstract[92]	new[91]|new[92]	_	_
13-10	1714-1721	fasting	abstract[91]|abstract[92]|abstract	new[91]|new[92]|giv	coref	15-18[106_0]
13-11	1722-1723	.	_	_	_	_

#Text=Several non-fatal ( e. g. , headache ) and rarely fatal ( e. g. , ventricular arrhythmia ) events have been reported .
14-1	1724-1731	Several	abstract[94]	new[94]	appos	14-4[95_94]
14-2	1732-1741	non-fatal	abstract[94]	new[94]	_	_
14-3	1742-1743	(	_	_	_	_
14-4	1744-1746	e.	abstract[95]	giv[95]	coref	23-10[166_95]
14-5	1747-1749	g.	abstract[95]|abstract	giv[95]|new	appos	14-7
14-6	1750-1751	,	_	_	_	_
14-7	1752-1760	headache	abstract	giv	_	_
14-8	1761-1762	)	_	_	_	_
14-9	1763-1766	and	_	_	_	_
14-10	1767-1773	rarely	_	_	_	_
14-11	1774-1779	fatal	_	_	_	_
14-12	1780-1781	(	_	_	_	_
14-13	1782-1784	e.	abstract	new	_	_
14-14	1785-1787	g.	_	_	_	_
14-15	1788-1789	,	_	_	_	_
14-16	1790-1801	ventricular	abstract|abstract[100]	new|new[100]	_	_
14-17	1802-1812	arrhythmia	abstract[100]	new[100]	_	_
14-18	1813-1814	)	_	_	_	_
14-19	1815-1821	events	event	new	coref	15-4[103_0]
14-20	1822-1826	have	_	_	_	_
14-21	1827-1831	been	_	_	_	_
14-22	1832-1840	reported	_	_	_	_
14-23	1841-1842	.	_	_	_	_

#Text=In contrast , no severe adverse events were found in a cohort of 1422 subjects treated with a periodic fasting lasting 4 – 21 days , . Michalsen et al. evaluated the acceptance , safety , effects on health-related outcomes , and lifestyle adherence of fasting therapy in different chronic internal diseases .
15-1	1843-1845	In	_	_	_	_
15-2	1846-1854	contrast	abstract	giv	_	_
15-3	1855-1856	,	_	_	_	_
15-4	1857-1859	no	event[103]	giv[103]	coref	16-3[120_103]
15-5	1860-1866	severe	event[103]	giv[103]	_	_
15-6	1867-1874	adverse	event[103]	giv[103]	_	_
15-7	1875-1881	events	event[103]	giv[103]	_	_
15-8	1882-1886	were	_	_	_	_
15-9	1887-1892	found	_	_	_	_
15-10	1893-1895	in	_	_	_	_
15-11	1896-1897	a	person[104]	new[104]	_	_
15-12	1898-1904	cohort	person[104]	new[104]	_	_
15-13	1905-1907	of	person[104]	new[104]	_	_
15-14	1908-1912	1422	person[104]|person[105]	new[104]|giv[105]	ana	16-1[0_105]
15-15	1913-1921	subjects	person[104]|person[105]	new[104]|giv[105]	_	_
15-16	1922-1929	treated	_	_	_	_
15-17	1930-1934	with	_	_	_	_
15-18	1935-1936	a	abstract[106]	giv[106]	coref	21-5[151_106]
15-19	1937-1945	periodic	abstract[106]	giv[106]	_	_
15-20	1946-1953	fasting	abstract[106]	giv[106]	_	_
15-21	1954-1961	lasting	_	_	_	_
15-22	1962-1963	4	time[107]	new[107]	coref	26-7[195_107]
15-23	1964-1965	–	time[107]	new[107]	_	_
15-24	1966-1968	21	time[107]|quantity	new[107]|new	_	_
15-25	1969-1973	days	time	new	_	_
15-26	1974-1975	,	_	_	_	_
15-27	1976-1977	.	_	_	_	_
15-28	1978-1987	Michalsen	person	new	_	_
15-29	1988-1990	et	_	_	_	_
15-30	1991-1994	al.	_	_	_	_
15-31	1995-2004	evaluated	_	_	_	_
15-32	2005-2008	the	abstract[111]	new[111]	_	_
15-33	2009-2019	acceptance	abstract[111]	new[111]	_	_
15-34	2020-2021	,	_	_	_	_
15-35	2022-2028	safety	abstract	new	_	_
15-36	2029-2030	,	_	_	_	_
15-37	2031-2038	effects	abstract[113]	giv[113]	_	_
15-38	2039-2041	on	abstract[113]	giv[113]	_	_
15-39	2042-2056	health-related	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
15-40	2057-2065	outcomes	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
15-41	2066-2067	,	_	_	_	_
15-42	2068-2071	and	_	_	_	_
15-43	2072-2081	lifestyle	abstract|event[116]	giv|giv[116]	_	_
15-44	2082-2091	adherence	event[116]	giv[116]	_	_
15-45	2092-2094	of	_	_	_	_
15-46	2095-2102	fasting	_	_	_	_
15-47	2103-2110	therapy	abstract	new	coref	17-7[126_0]
15-48	2111-2113	in	_	_	_	_
15-49	2114-2123	different	abstract[118]	new[118]	_	_
15-50	2124-2131	chronic	abstract[118]	new[118]	_	_
15-51	2132-2140	internal	abstract[118]	new[118]	_	_
15-52	2141-2149	diseases	abstract[118]	new[118]	_	_
15-53	2150-2151	.	_	_	_	_

#Text=They found no serious adverse events throughout their study .
16-1	2152-2156	They	person	giv	ana	16-8
16-2	2157-2162	found	_	_	_	_
16-3	2163-2165	no	event[120]	giv[120]	_	_
16-4	2166-2173	serious	event[120]	giv[120]	_	_
16-5	2174-2181	adverse	event[120]	giv[120]	_	_
16-6	2182-2188	events	event[120]	giv[120]	_	_
16-7	2189-2199	throughout	_	_	_	_
16-8	2200-2205	their	person|abstract[122]	giv|giv[122]	coref|coref	17-1[124_122]|17-1[124_122]
16-9	2206-2211	study	abstract[122]	giv[122]	_	_
16-10	2212-2213	.	_	_	_	_

#Text=Our study supports the hypothesis that fasting therapy provided in a controlled clinical setting is a safe intervention .
17-1	2214-2217	Our	person|abstract[124]	giv|giv[124]	ana|coref|ana|coref	28-1|37-13[270_124]|28-1|37-13[270_124]
17-2	2218-2223	study	abstract[124]	giv[124]	_	_
17-3	2224-2232	supports	_	_	_	_
17-4	2233-2236	the	abstract[125]	giv[125]	_	_
17-5	2237-2247	hypothesis	abstract[125]	giv[125]	_	_
17-6	2248-2252	that	_	_	_	_
17-7	2253-2260	fasting	event[126]	giv[126]	coref	17-16[128_126]
17-8	2261-2268	therapy	event[126]	giv[126]	_	_
17-9	2269-2277	provided	_	_	_	_
17-10	2278-2280	in	_	_	_	_
17-11	2281-2282	a	abstract[127]	new[127]	_	_
17-12	2283-2293	controlled	abstract[127]	new[127]	_	_
17-13	2294-2302	clinical	abstract[127]	new[127]	_	_
17-14	2303-2310	setting	abstract[127]	new[127]	_	_
17-15	2311-2313	is	_	_	_	_
17-16	2314-2315	a	event[128]	giv[128]	coref	31-4[227_128]
17-17	2316-2320	safe	event[128]	giv[128]	_	_
17-18	2321-2333	intervention	event[128]	giv[128]	_	_
17-19	2334-2335	.	_	_	_	_

#Text=There is a large body of evidence on the beneficial effects of carbohydrate restriction and hypocaloric diets on NAFLD .
18-1	2336-2341	There	_	_	_	_
18-2	2342-2344	is	_	_	_	_
18-3	2345-2346	a	object[129]	giv[129]	_	_
18-4	2347-2352	large	object[129]	giv[129]	_	_
18-5	2353-2357	body	object[129]	giv[129]	_	_
18-6	2358-2360	of	object[129]	giv[129]	_	_
18-7	2361-2369	evidence	object[129]|abstract[130]	giv[129]|giv[130]	ana	19-1[0_130]
18-8	2370-2372	on	object[129]|abstract[130]	giv[129]|giv[130]	_	_
18-9	2373-2376	the	object[129]|abstract[130]|abstract[131]	giv[129]|giv[130]|new[131]	coref	22-4[157_131]
18-10	2377-2387	beneficial	object[129]|abstract[130]|abstract[131]	giv[129]|giv[130]|new[131]	_	_
18-11	2388-2395	effects	object[129]|abstract[130]|abstract[131]	giv[129]|giv[130]|new[131]	_	_
18-12	2396-2398	of	object[129]|abstract[130]|abstract[131]	giv[129]|giv[130]|new[131]	_	_
18-13	2399-2411	carbohydrate	object[129]|abstract[130]|abstract[131]|abstract|abstract[133]	giv[129]|giv[130]|new[131]|new|new[133]	coref|coref|coref|coref	20-5|20-5[146_133]|20-5|20-5[146_133]
18-14	2412-2423	restriction	object[129]|abstract[130]|abstract[131]|abstract[133]	giv[129]|giv[130]|new[131]|new[133]	_	_
18-15	2424-2427	and	object[129]|abstract[130]|abstract[131]	giv[129]|giv[130]|new[131]	_	_
18-16	2428-2439	hypocaloric	object[129]|abstract[130]|abstract[131]|abstract[134]	giv[129]|giv[130]|new[131]|new[134]	_	_
18-17	2440-2445	diets	object[129]|abstract[130]|abstract[131]|abstract[134]	giv[129]|giv[130]|new[131]|new[134]	_	_
18-18	2446-2448	on	object[129]|abstract[130]|abstract[131]|abstract[134]	giv[129]|giv[130]|new[131]|new[134]	_	_
18-19	2449-2454	NAFLD	object[129]|abstract[130]|abstract[131]|abstract[134]|substance	giv[129]|giv[130]|new[131]|new[134]|giv	coref	27-28
18-20	2455-2456	.	_	_	_	_

#Text=It has also been shown that-at equal levels of weight reduction-a carbohydrate-restricted diet leads to a significantly greater intrahepatic triglyceride reduction than low-calorie diet alone .
19-1	2457-2459	It	abstract	giv	coref	27-4[201_0]
19-2	2460-2463	has	_	_	_	_
19-3	2464-2468	also	_	_	_	_
19-4	2469-2473	been	_	_	_	_
19-5	2474-2479	shown	_	_	_	_
19-6	2480-2487	that-at	_	_	_	_
19-7	2488-2493	equal	abstract[137]	new[137]	coref	31-22[232_137]
19-8	2494-2500	levels	abstract[137]	new[137]	_	_
19-9	2501-2503	of	abstract[137]	new[137]	_	_
19-10	2504-2510	weight	abstract[137]|abstract	new[137]|giv	coref	22-5
19-11	2511-2522	reduction-a	event[139]	new[139]	coref	19-23[142_139]
19-12	2523-2546	carbohydrate-restricted	event[139]	new[139]	_	_
19-13	2547-2551	diet	event[139]	new[139]	_	_
19-14	2552-2557	leads	_	_	_	_
19-15	2558-2560	to	_	_	_	_
19-16	2561-2562	a	abstract[141]	giv[141]	_	_
19-17	2563-2576	significantly	abstract[141]	giv[141]	_	_
19-18	2577-2584	greater	abstract[141]	giv[141]	_	_
19-19	2585-2597	intrahepatic	abstract[141]	giv[141]	_	_
19-20	2598-2610	triglyceride	abstract|abstract[141]	new|giv[141]	_	_
19-21	2611-2620	reduction	abstract[141]	giv[141]	_	_
19-22	2621-2625	than	abstract[141]	giv[141]	_	_
19-23	2626-2637	low-calorie	abstract[141]|event[142]	giv[141]|giv[142]	_	_
19-24	2638-2642	diet	abstract[141]|event[142]	giv[141]|giv[142]	_	_
19-25	2643-2648	alone	abstract[141]|event[142]	giv[141]|giv[142]	_	_
19-26	2649-2650	.	_	_	_	_

#Text=The metabolic advantage of carbohydrate restriction appears to be related to a more pronounced lipid oxidation and enhanced ketogenesis .
20-1	2651-2654	The	abstract[144]	new[144]	_	_
20-2	2655-2664	metabolic	person|abstract[144]	giv|new[144]	coref	22-15
20-3	2665-2674	advantage	abstract[144]	new[144]	_	_
20-4	2675-2677	of	abstract[144]	new[144]	_	_
20-5	2678-2690	carbohydrate	abstract[144]|abstract|abstract[146]	new[144]|giv|giv[146]	coref|coref	21-16[154_146]|21-16[154_146]
20-6	2691-2702	restriction	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
20-7	2703-2710	appears	_	_	_	_
20-8	2711-2713	to	_	_	_	_
20-9	2714-2716	be	_	_	_	_
20-10	2717-2724	related	_	_	_	_
20-11	2725-2727	to	_	_	_	_
20-12	2728-2729	a	abstract[148]	new[148]	_	_
20-13	2730-2734	more	abstract[148]	new[148]	_	_
20-14	2735-2745	pronounced	abstract[148]	new[148]	_	_
20-15	2746-2751	lipid	person|abstract[148]	new|new[148]	coref	22-22
20-16	2752-2761	oxidation	abstract[148]	new[148]	_	_
20-17	2762-2765	and	_	_	_	_
20-18	2766-2774	enhanced	substance[149]	new[149]	coref	26-3[0_149]
20-19	2775-2786	ketogenesis	substance[149]	new[149]	_	_
20-20	2787-2788	.	_	_	_	_

#Text=In recent years , intermittent and periodic fasting has gained popularity as an alternative to continuous caloric restriction .
21-1	2789-2791	In	_	_	_	_
21-2	2792-2798	recent	time[150]	new[150]	_	_
21-3	2799-2804	years	time[150]	new[150]	_	_
21-4	2805-2806	,	_	_	_	_
21-5	2807-2819	intermittent	abstract[151]	giv[151]	coref	22-9[158_151]
21-6	2820-2823	and	abstract[151]	giv[151]	_	_
21-7	2824-2832	periodic	abstract[151]	giv[151]	_	_
21-8	2833-2840	fasting	abstract[151]	giv[151]	_	_
21-9	2841-2844	has	_	_	_	_
21-10	2845-2851	gained	_	_	_	_
21-11	2852-2862	popularity	abstract	new	_	_
21-12	2863-2865	as	_	_	_	_
21-13	2866-2868	an	_	_	_	_
21-14	2869-2880	alternative	_	_	_	_
21-15	2881-2883	to	_	_	_	_
21-16	2884-2894	continuous	abstract[154]	giv[154]	_	_
21-17	2895-2902	caloric	abstract|abstract[154]	new|giv[154]	_	_
21-18	2903-2914	restriction	abstract[154]	giv[154]	_	_
21-19	2915-2916	.	_	_	_	_

#Text=In addition to the weight loss effects , periodic fasting is associated with several metabolic benefits , including the improvement of lipid profiles .
22-1	2917-2919	In	_	_	_	_
22-2	2920-2928	addition	_	_	_	_
22-3	2929-2931	to	_	_	_	_
22-4	2932-2935	the	abstract[157]	giv[157]	coref	24-8[170_157]
22-5	2936-2942	weight	abstract|abstract[157]	giv|giv[157]	_	_
22-6	2943-2947	loss	abstract|abstract[157]	giv|giv[157]	_	_
22-7	2948-2955	effects	abstract[157]	giv[157]	_	_
22-8	2956-2957	,	_	_	_	_
22-9	2958-2966	periodic	abstract[158]	giv[158]	coref	23-7[165_158]
22-10	2967-2974	fasting	abstract[158]	giv[158]	_	_
22-11	2975-2977	is	_	_	_	_
22-12	2978-2988	associated	_	_	_	_
22-13	2989-2993	with	_	_	_	_
22-14	2994-3001	several	abstract[160]	new[160]	_	_
22-15	3002-3011	metabolic	person|abstract[160]	giv|new[160]	coref	24-13
22-16	3012-3020	benefits	abstract[160]	new[160]	_	_
22-17	3021-3022	,	_	_	_	_
22-18	3023-3032	including	_	_	_	_
22-19	3033-3036	the	abstract[161]	new[161]	ana	23-1[0_161]
22-20	3037-3048	improvement	abstract[161]	new[161]	_	_
22-21	3049-3051	of	abstract[161]	new[161]	_	_
22-22	3052-3057	lipid	abstract[161]|person|abstract[163]	new[161]|giv|new[163]	_	_
22-23	3058-3066	profiles	abstract[161]|abstract[163]	new[161]|new[163]	_	_
22-24	3067-3068	.	_	_	_	_

#Text=This has been also shown for intermittent fasting , e. g. , Ramadan fasting .
23-1	3069-3073	This	abstract	giv	_	_
23-2	3074-3077	has	_	_	_	_
23-3	3078-3082	been	_	_	_	_
23-4	3083-3087	also	_	_	_	_
23-5	3088-3093	shown	_	_	_	_
23-6	3094-3097	for	_	_	_	_
23-7	3098-3110	intermittent	abstract[165]	giv[165]	coref	23-13[168_165]
23-8	3111-3118	fasting	abstract[165]	giv[165]	_	_
23-9	3119-3120	,	_	_	_	_
23-10	3121-3123	e.	abstract[166]	giv[166]	coref	37-45[280_166]
23-11	3124-3126	g.	abstract[166]	giv[166]	_	_
23-12	3127-3128	,	_	_	_	_
23-13	3129-3136	Ramadan	person|abstract[168]	new|giv[168]	coref|coref	28-7[214_168]|28-7[214_168]
23-14	3137-3144	fasting	abstract[168]	giv[168]	_	_
23-15	3145-3146	.	_	_	_	_

#Text=The key mechanism responsible for many of these beneficial effects is the metabolic switch from the utilization of glycogenolysis-derived glucose to fatty acids and fatty acid-derived ketones , i. e. , a fundamental switch from lipid synthesis and fat storage to mobilization of fat in the form of free fatty acids and fatty acid-derived ketones .
24-1	3147-3150	The	object[169]	new[169]	coref	24-12[172_169]
24-2	3151-3154	key	object[169]	new[169]	_	_
24-3	3155-3164	mechanism	object[169]	new[169]	_	_
24-4	3165-3176	responsible	object[169]	new[169]	_	_
24-5	3177-3180	for	_	_	_	_
24-6	3181-3185	many	_	_	_	_
24-7	3186-3188	of	_	_	_	_
24-8	3189-3194	these	abstract[170]	giv[170]	_	_
24-9	3195-3205	beneficial	abstract[170]	giv[170]	_	_
24-10	3206-3213	effects	abstract[170]	giv[170]	_	_
24-11	3214-3216	is	_	_	_	_
24-12	3217-3220	the	object[172]	giv[172]	_	_
24-13	3221-3230	metabolic	person|object[172]	giv|giv[172]	_	_
24-14	3231-3237	switch	object[172]	giv[172]	_	_
24-15	3238-3242	from	object[172]	giv[172]	_	_
24-16	3243-3246	the	object[172]|abstract[173]	giv[172]|new[173]	_	_
24-17	3247-3258	utilization	object[172]|abstract[173]	giv[172]|new[173]	_	_
24-18	3259-3261	of	object[172]|abstract[173]	giv[172]|new[173]	_	_
24-19	3262-3284	glycogenolysis-derived	object[172]|abstract[173]|substance[174]	giv[172]|new[173]|new[174]	_	_
24-20	3285-3292	glucose	object[172]|abstract[173]|substance[174]	giv[172]|new[173]|new[174]	_	_
24-21	3293-3295	to	object[172]|abstract[173]	giv[172]|new[173]	_	_
24-22	3296-3301	fatty	object[172]|abstract[173]|substance[175]|substance[176]	giv[172]|new[173]|new[175]|new[176]	coref|coref|coref|coref	24-49[185_175]|24-49[186_176]|24-49[185_175]|24-49[186_176]
24-23	3302-3307	acids	object[172]|abstract[173]|substance[175]|substance[176]	giv[172]|new[173]|new[175]|new[176]	_	_
24-24	3308-3311	and	object[172]|abstract[173]|substance[176]	giv[172]|new[173]|new[176]	_	_
24-25	3312-3317	fatty	object[172]|abstract[173]|substance[176]|substance[177]	giv[172]|new[173]|new[176]|new[177]	coref	24-53[187_177]
24-26	3318-3330	acid-derived	object[172]|abstract[173]|substance[176]|substance[177]	giv[172]|new[173]|new[176]|new[177]	_	_
24-27	3331-3338	ketones	object[172]|abstract[173]|substance[176]|substance[177]	giv[172]|new[173]|new[176]|new[177]	_	_
24-28	3339-3340	,	object[172]	giv[172]	_	_
24-29	3341-3343	i.	object[172]	giv[172]	_	_
24-30	3344-3346	e.	object[172]	giv[172]	_	_
24-31	3347-3348	,	object[172]	giv[172]	_	_
24-32	3349-3350	a	object[172]	giv[172]	_	_
24-33	3351-3362	fundamental	object[172]	giv[172]	_	_
24-34	3363-3369	switch	object[172]	giv[172]	_	_
24-35	3370-3374	from	object[172]	giv[172]	_	_
24-36	3375-3380	lipid	object[172]|abstract|abstract[179]	giv[172]|new|new[179]	coref|coref	40-22|40-22
24-37	3381-3390	synthesis	object[172]|abstract[179]	giv[172]|new[179]	_	_
24-38	3391-3394	and	object[172]	giv[172]	_	_
24-39	3395-3398	fat	object[172]|substance|abstract[181]	giv[172]|new|new[181]	coref|coref	24-44[183_0]|24-44[183_0]
24-40	3399-3406	storage	object[172]|abstract[181]	giv[172]|new[181]	_	_
24-41	3407-3409	to	object[172]	giv[172]	_	_
24-42	3410-3422	mobilization	object[172]|abstract[182]	giv[172]|new[182]	_	_
24-43	3423-3425	of	object[172]|abstract[182]	giv[172]|new[182]	_	_
24-44	3426-3429	fat	object[172]|abstract[182]|substance[183]	giv[172]|new[182]|giv[183]	coref	28-14[217_183]
24-45	3430-3432	in	object[172]|abstract[182]|substance[183]	giv[172]|new[182]|giv[183]	_	_
24-46	3433-3436	the	object[172]|abstract[182]|substance[183]|abstract[184]	giv[172]|new[182]|giv[183]|new[184]	ana	25-1[0_184]
24-47	3437-3441	form	object[172]|abstract[182]|substance[183]|abstract[184]	giv[172]|new[182]|giv[183]|new[184]	_	_
24-48	3442-3444	of	object[172]|abstract[182]|substance[183]|abstract[184]	giv[172]|new[182]|giv[183]|new[184]	_	_
24-49	3445-3449	free	object[172]|abstract[182]|substance[183]|abstract[184]|substance[185]|substance[186]	giv[172]|new[182]|giv[183]|new[184]|giv[185]|giv[186]	_	_
24-50	3450-3455	fatty	object[172]|abstract[182]|substance[183]|abstract[184]|substance[185]|substance[186]	giv[172]|new[182]|giv[183]|new[184]|giv[185]|giv[186]	_	_
24-51	3456-3461	acids	object[172]|abstract[182]|substance[183]|abstract[184]|substance[185]|substance[186]	giv[172]|new[182]|giv[183]|new[184]|giv[185]|giv[186]	_	_
24-52	3462-3465	and	object[172]|abstract[182]|substance[183]|abstract[184]|substance[186]	giv[172]|new[182]|giv[183]|new[184]|giv[186]	_	_
24-53	3466-3471	fatty	object[172]|abstract[182]|substance[183]|abstract[184]|substance[186]|substance[187]	giv[172]|new[182]|giv[183]|new[184]|giv[186]|giv[187]	_	_
24-54	3472-3484	acid-derived	object[172]|abstract[182]|substance[183]|abstract[184]|substance[186]|substance[187]	giv[172]|new[182]|giv[183]|new[184]|giv[186]|giv[187]	_	_
24-55	3485-3492	ketones	object[172]|abstract[182]|substance[183]|abstract[184]|substance[186]|substance[187]	giv[172]|new[182]|giv[183]|new[184]|giv[186]|giv[187]	_	_
24-56	3493-3494	.	_	_	_	_

#Text=This occurs between 12 and 36 hours after cessation of food consumption .
25-1	3495-3499	This	abstract	giv	_	_
25-2	3500-3506	occurs	_	_	_	_
25-3	3507-3514	between	_	_	_	_
25-4	3515-3517	12	time[189]	new[189]	_	_
25-5	3518-3521	and	time[189]	new[189]	_	_
25-6	3522-3524	36	time[189]	new[189]	_	_
25-7	3525-3530	hours	time[189]	new[189]	_	_
25-8	3531-3536	after	_	_	_	_
25-9	3537-3546	cessation	event[190]	new[190]	_	_
25-10	3547-3549	of	event[190]	new[190]	_	_
25-11	3550-3554	food	event[190]|substance|abstract[192]	new[190]|new|new[192]	_	_
25-12	3555-3566	consumption	event[190]|abstract[192]	new[190]|new[192]	_	_
25-13	3567-3568	.	_	_	_	_

#Text=Hyperinsulinemia suppresses ketogenesis and therefore prolongs the time to switch in cases of obesity , insulin resistance , and T2DM .
26-1	3569-3585	Hyperinsulinemia	abstract	new	_	_
26-2	3586-3596	suppresses	_	_	_	_
26-3	3597-3608	ketogenesis	substance	giv	coref	27-7[202_0]
26-4	3609-3612	and	_	_	_	_
26-5	3613-3622	therefore	_	_	_	_
26-6	3623-3631	prolongs	_	_	_	_
26-7	3632-3635	the	time[195]	giv[195]	_	_
26-8	3636-3640	time	time[195]	giv[195]	_	_
26-9	3641-3643	to	_	_	_	_
26-10	3644-3650	switch	_	_	_	_
26-11	3651-3653	in	_	_	_	_
26-12	3654-3659	cases	abstract[196]	new[196]	_	_
26-13	3660-3662	of	abstract[196]	new[196]	_	_
26-14	3663-3670	obesity	abstract[196]|abstract	new[196]|giv	_	_
26-15	3671-3672	,	abstract[196]	new[196]	_	_
26-16	3673-3680	insulin	abstract[196]|event|abstract[199]	new[196]|giv|giv[199]	coref|coref|coref|coref	36-5|36-5[255_199]|36-5|36-5[255_199]
26-17	3681-3691	resistance	abstract[196]|abstract[199]	new[196]|giv[199]	_	_
26-18	3692-3693	,	abstract[196]	new[196]	_	_
26-19	3694-3697	and	abstract[196]	new[196]	_	_
26-20	3698-3702	T2DM	abstract[196]|abstract	new[196]|giv	coref	36-8
26-21	3703-3704	.	_	_	_	_

#Text=Although there is some evidence of impaired ketogenesis during the progression of liver disease to steatohepatitis , therapies that increase hepatic ketogenesis are expected nonetheless to ameliorate NAFLD .
27-1	3705-3713	Although	_	_	_	_
27-2	3714-3719	there	_	_	_	_
27-3	3720-3722	is	_	_	_	_
27-4	3723-3727	some	abstract[201]	giv[201]	coref	28-4[213_201]
27-5	3728-3736	evidence	abstract[201]	giv[201]	_	_
27-6	3737-3739	of	abstract[201]	giv[201]	_	_
27-7	3740-3748	impaired	abstract[201]|substance[202]	giv[201]|giv[202]	_	_
27-8	3749-3760	ketogenesis	abstract[201]|substance[202]	giv[201]|giv[202]	_	_
27-9	3761-3767	during	abstract[201]	giv[201]	_	_
27-10	3768-3771	the	abstract[201]|event[203]	giv[201]|new[203]	_	_
27-11	3772-3783	progression	abstract[201]|event[203]	giv[201]|new[203]	_	_
27-12	3784-3786	of	abstract[201]|event[203]	giv[201]|new[203]	_	_
27-13	3787-3792	liver	abstract[201]|event[203]|object|abstract[205]	giv[201]|new[203]|giv|new[205]	coref|coref	28-14|28-14
27-14	3793-3800	disease	abstract[201]|event[203]|abstract[205]	giv[201]|new[203]|new[205]	_	_
27-15	3801-3803	to	abstract[201]|event[203]|abstract[205]	giv[201]|new[203]|new[205]	_	_
27-16	3804-3819	steatohepatitis	abstract[201]|event[203]|abstract[205]|abstract	giv[201]|new[203]|new[205]|new	_	_
27-17	3820-3821	,	abstract[201]|event[203]|abstract[205]	giv[201]|new[203]|new[205]	_	_
27-18	3822-3831	therapies	abstract[201]|event[203]|abstract[205]|object	giv[201]|new[203]|new[205]|new	_	_
27-19	3832-3836	that	_	_	_	_
27-20	3837-3845	increase	_	_	_	_
27-21	3846-3853	hepatic	abstract|abstract[209]	new|new[209]	_	_
27-22	3854-3865	ketogenesis	abstract[209]	new[209]	_	_
27-23	3866-3869	are	_	_	_	_
27-24	3870-3878	expected	_	_	_	_
27-25	3879-3890	nonetheless	_	_	_	_
27-26	3891-3893	to	_	_	_	_
27-27	3894-3904	ameliorate	_	_	_	_
27-28	3905-3910	NAFLD	substance	giv	coref	28-28
27-29	3911-3912	.	_	_	_	_

#Text=Our data provided first evidence that periodic fasting leads to a clearance of liver fat : fasting significantly reduced FLI and increased the proportion of patients without NAFLD ( FLI < 30 units ;
28-1	3913-3916	Our	person|abstract[212]	giv|new[212]	ana|ana	37-16|37-16
28-2	3917-3921	data	abstract[212]	new[212]	_	_
28-3	3922-3930	provided	_	_	_	_
28-4	3931-3936	first	abstract[213]	giv[213]	_	_
28-5	3937-3945	evidence	abstract[213]	giv[213]	_	_
28-6	3946-3950	that	_	_	_	_
28-7	3951-3959	periodic	abstract[214]	giv[214]	coref	31-4[0_214]
28-8	3960-3967	fasting	abstract[214]	giv[214]	_	_
28-9	3968-3973	leads	_	_	_	_
28-10	3974-3976	to	_	_	_	_
28-11	3977-3978	a	abstract[215]	new[215]	_	_
28-12	3979-3988	clearance	abstract[215]	new[215]	_	_
28-13	3989-3991	of	abstract[215]	new[215]	_	_
28-14	3992-3997	liver	abstract[215]|object|substance[217]	new[215]|giv|giv[217]	coref|coref|coref|coref	33-19[242_0]|36-33[265_217]|33-19[242_0]|36-33[265_217]
28-15	3998-4001	fat	abstract[215]|substance[217]	new[215]|giv[217]	_	_
28-16	4002-4003	:	_	_	_	_
28-17	4004-4011	fasting	_	_	_	_
28-18	4012-4025	significantly	_	_	_	_
28-19	4026-4033	reduced	_	_	_	_
28-20	4034-4037	FLI	abstract	giv	coref	28-30
28-21	4038-4041	and	_	_	_	_
28-22	4042-4051	increased	_	_	_	_
28-23	4052-4055	the	abstract[219]	new[219]	_	_
28-24	4056-4066	proportion	abstract[219]	new[219]	_	_
28-25	4067-4069	of	abstract[219]	new[219]	_	_
28-26	4070-4078	patients	abstract[219]|person[220]	new[219]|giv[220]	coref	37-1[266_220]
28-27	4079-4086	without	abstract[219]|person[220]	new[219]|giv[220]	_	_
28-28	4087-4092	NAFLD	abstract[219]|person[220]|quantity	new[219]|giv[220]|giv	coref	35-15
28-29	4093-4094	(	_	_	_	_
28-30	4095-4098	FLI	abstract	giv	coref	31-14[231_0]
28-31	4099-4100	<	_	_	_	_
28-32	4101-4103	30	quantity[223]	new[223]	_	_
28-33	4104-4109	units	quantity[223]	new[223]	_	_
28-34	4110-4111	;	_	_	_	_

#Text=Figure 2
29-1	4112-4118	Figure	abstract[224]	new[224]	_	_
29-2	4119-4120	2	abstract[224]	new[224]	_	_

#Text=) .
30-1	4121-4122	)	_	_	_	_
30-2	4123-4124	.	_	_	_	_

#Text=The effects of fasting therapy were stronger in males and in individuals with higher baseline FLI , higher GOT , and higher cholesterol levels .
31-1	4125-4128	The	abstract[225]	new[225]	_	_
31-2	4129-4136	effects	abstract[225]	new[225]	_	_
31-3	4137-4139	of	abstract[225]	new[225]	_	_
31-4	4140-4147	fasting	abstract[225]|abstract|abstract[227]	new[225]|giv|giv[227]	coref|coref|coref|coref	32-3|37-20[273_227]|32-3|37-20[273_227]
31-5	4148-4155	therapy	abstract[225]|abstract[227]	new[225]|giv[227]	_	_
31-6	4156-4160	were	_	_	_	_
31-7	4161-4169	stronger	_	_	_	_
31-8	4170-4172	in	_	_	_	_
31-9	4173-4178	males	person	new	_	_
31-10	4179-4182	and	_	_	_	_
31-11	4183-4185	in	_	_	_	_
31-12	4186-4197	individuals	person[229]	new[229]	_	_
31-13	4198-4202	with	person[229]	new[229]	_	_
31-14	4203-4209	higher	person[229]|abstract[231]	new[229]|giv[231]	coref	32-7[235_231]
31-15	4210-4218	baseline	person[229]|abstract|abstract[231]	new[229]|new|giv[231]	_	_
31-16	4219-4222	FLI	person[229]|abstract[231]	new[229]|giv[231]	_	_
31-17	4223-4224	,	_	_	_	_
31-18	4225-4231	higher	_	_	_	_
31-19	4232-4235	GOT	_	_	_	_
31-20	4236-4237	,	_	_	_	_
31-21	4238-4241	and	_	_	_	_
31-22	4242-4248	higher	abstract[232]	giv[232]	coref	39-8[292_232]
31-23	4249-4260	cholesterol	abstract[232]	giv[232]	_	_
31-24	4261-4267	levels	abstract[232]	giv[232]	_	_
31-25	4268-4269	.	_	_	_	_

#Text=Each additional fasting day further decreased the FLI .
32-1	4270-4274	Each	time[234]	new[234]	_	_
32-2	4275-4285	additional	time[234]	new[234]	_	_
32-3	4286-4293	fasting	abstract|time[234]	giv|new[234]	coref	33-10
32-4	4294-4297	day	time[234]	new[234]	_	_
32-5	4298-4305	further	_	_	_	_
32-6	4306-4315	decreased	_	_	_	_
32-7	4316-4319	the	abstract[235]	giv[235]	coref	33-24[243_235]
32-8	4320-4323	FLI	abstract[235]	giv[235]	_	_
32-9	4324-4325	.	_	_	_	_

#Text=The binary logistic regression showed that every day of fasting increase by 40 % the chance to improve a manifest fatty liver ( FLI > 60 ) and switch to a lower category of risk .
33-1	4326-4329	The	abstract[236]	new[236]	_	_
33-2	4330-4336	binary	abstract[236]	new[236]	_	_
33-3	4337-4345	logistic	abstract[236]	new[236]	_	_
33-4	4346-4356	regression	abstract[236]	new[236]	_	_
33-5	4357-4363	showed	_	_	_	_
33-6	4364-4368	that	_	_	_	_
33-7	4369-4374	every	_	_	_	_
33-8	4375-4378	day	_	_	_	_
33-9	4379-4381	of	_	_	_	_
33-10	4382-4389	fasting	abstract|abstract[238]	giv|new[238]	coref|coref	34-7|34-7
33-11	4390-4398	increase	abstract[238]	new[238]	_	_
33-12	4399-4401	by	abstract[238]	new[238]	_	_
33-13	4402-4404	40	abstract[238]|quantity[239]	new[238]|new[239]	_	_
33-14	4405-4406	%	abstract[238]|quantity[239]	new[238]|new[239]	_	_
33-15	4407-4410	the	abstract[240]	new[240]	_	_
33-16	4411-4417	chance	abstract[240]	new[240]	_	_
33-17	4418-4420	to	_	_	_	_
33-18	4421-4428	improve	abstract	new	coref	37-39[278_0]
33-19	4429-4430	a	object[242]	giv[242]	coref	34-13[249_242]
33-20	4431-4439	manifest	object[242]	giv[242]	_	_
33-21	4440-4445	fatty	animal|object[242]	new|giv[242]	_	_
33-22	4446-4451	liver	object[242]	giv[242]	_	_
33-23	4452-4453	(	_	_	_	_
33-24	4454-4457	FLI	abstract[243]	giv[243]	coref	37-8[0_243]
33-25	4458-4459	>	abstract[243]	giv[243]	_	_
33-26	4460-4462	60	abstract[243]	giv[243]	_	_
33-27	4463-4464	)	_	_	_	_
33-28	4465-4468	and	_	_	_	_
33-29	4469-4475	switch	_	_	_	_
33-30	4476-4478	to	_	_	_	_
33-31	4479-4480	a	abstract[244]	new[244]	_	_
33-32	4481-4486	lower	abstract[244]	new[244]	_	_
33-33	4487-4495	category	abstract[244]	new[244]	_	_
33-34	4496-4498	of	abstract[244]	new[244]	_	_
33-35	4499-4503	risk	abstract[244]|abstract	new[244]|new	ana	34-1
33-36	4504-4505	.	_	_	_	_

#Text=This implies that the duration of fasting must be sufficient to influence fatty liver positively .
34-1	4506-4510	This	abstract	giv	ana	35-1
34-2	4511-4518	implies	_	_	_	_
34-3	4519-4523	that	_	_	_	_
34-4	4524-4527	the	abstract[247]	new[247]	_	_
34-5	4528-4536	duration	abstract[247]	new[247]	_	_
34-6	4537-4539	of	abstract[247]	new[247]	_	_
34-7	4540-4547	fasting	abstract[247]|abstract	new[247]|giv	coref	35-8[252_0]
34-8	4548-4552	must	_	_	_	_
34-9	4553-4555	be	_	_	_	_
34-10	4556-4566	sufficient	_	_	_	_
34-11	4567-4569	to	_	_	_	_
34-12	4570-4579	influence	_	_	_	_
34-13	4580-4585	fatty	object[249]	giv[249]	coref	36-33[0_249]
34-14	4586-4591	liver	object[249]	giv[249]	_	_
34-15	4592-4602	positively	_	_	_	_
34-16	4603-4604	.	_	_	_	_

#Text=This should be taken into account when periodic fasting is considered as treatment for NAFLD .
35-1	4605-4609	This	abstract	giv	_	_
35-2	4610-4616	should	_	_	_	_
35-3	4617-4619	be	_	_	_	_
35-4	4620-4625	taken	_	_	_	_
35-5	4626-4630	into	_	_	_	_
35-6	4631-4638	account	abstract	new	_	_
35-7	4639-4643	when	_	_	_	_
35-8	4644-4652	periodic	abstract[252]	giv[252]	coref	37-21[0_252]
35-9	4653-4660	fasting	abstract[252]	giv[252]	_	_
35-10	4661-4663	is	_	_	_	_
35-11	4664-4674	considered	_	_	_	_
35-12	4675-4677	as	_	_	_	_
35-13	4678-4687	treatment	_	_	_	_
35-14	4688-4691	for	_	_	_	_
35-15	4692-4697	NAFLD	abstract	giv	coref	36-14
35-16	4698-4699	.	_	_	_	_

#Text=As already mentioned , insulin resistance , T2DM , and the development of NAFLD are closely associated conditions . Taylor et al. have shown that remission of T2DM requires a decrease of liver fat .
36-1	4700-4702	As	_	_	_	_
36-2	4703-4710	already	_	_	_	_
36-3	4711-4720	mentioned	_	_	_	_
36-4	4721-4722	,	_	_	_	_
36-5	4723-4730	insulin	event|abstract[255]	giv|giv[255]	coref|coref|coref|coref	39-4|39-4[291_255]|39-4|39-4[291_255]
36-6	4731-4741	resistance	abstract[255]	giv[255]	_	_
36-7	4742-4743	,	_	_	_	_
36-8	4744-4748	T2DM	event	giv	coref	36-28
36-9	4749-4750	,	_	_	_	_
36-10	4751-4754	and	_	_	_	_
36-11	4755-4758	the	event[257]	new[257]	_	_
36-12	4759-4770	development	event[257]	new[257]	_	_
36-13	4771-4773	of	event[257]	new[257]	_	_
36-14	4774-4779	NAFLD	event[257]|abstract	new[257]|giv	coref	39-13
36-15	4780-4783	are	_	_	_	_
36-16	4784-4791	closely	_	_	_	_
36-17	4792-4802	associated	_	_	_	_
36-18	4803-4813	conditions	abstract	new	_	_
36-19	4814-4815	.	_	_	_	_
36-20	4816-4822	Taylor	person	new	_	_
36-21	4823-4825	et	_	_	_	_
36-22	4826-4829	al.	_	_	_	_
36-23	4830-4834	have	_	_	_	_
36-24	4835-4840	shown	_	_	_	_
36-25	4841-4845	that	_	_	_	_
36-26	4846-4855	remission	event[261]	new[261]	_	_
36-27	4856-4858	of	event[261]	new[261]	_	_
36-28	4859-4863	T2DM	event[261]|event	new[261]|giv	coref	37-3
36-29	4864-4872	requires	_	_	_	_
36-30	4873-4874	a	abstract[263]	new[263]	_	_
36-31	4875-4883	decrease	abstract[263]	new[263]	_	_
36-32	4884-4886	of	abstract[263]	new[263]	_	_
36-33	4887-4892	liver	abstract[263]|object|substance[265]	new[263]|giv|giv[265]	coref|coref	39-1|39-1
36-34	4893-4896	fat	abstract[263]|substance[265]	new[263]|giv[265]	_	_
36-35	4897-4898	.	_	_	_	_

#Text=Patients with T2DM tend to have higher FLI scores , but in this study , we could demonstrate that the fasting intervention was equally effective in T2DM patients and in non-diabetic subjects in terms of FLI , although the improvement of other parameters ( e. g. , HDL , LDL , and AP ) was not as complete .
37-1	4899-4907	Patients	person[266]	giv[266]	coref	37-27[275_266]
37-2	4908-4912	with	person[266]	giv[266]	_	_
37-3	4913-4917	T2DM	person[266]|abstract	giv[266]|giv	coref	37-27
37-4	4918-4922	tend	_	_	_	_
37-5	4923-4925	to	_	_	_	_
37-6	4926-4930	have	_	_	_	_
37-7	4931-4937	higher	abstract[269]	new[269]	_	_
37-8	4938-4941	FLI	abstract|abstract[269]	giv|new[269]	coref	37-36
37-9	4942-4948	scores	abstract[269]	new[269]	_	_
37-10	4949-4950	,	_	_	_	_
37-11	4951-4954	but	_	_	_	_
37-12	4955-4957	in	_	_	_	_
37-13	4958-4962	this	abstract[270]	giv[270]	coref	38-7[285_270]
37-14	4963-4968	study	abstract[270]	giv[270]	_	_
37-15	4969-4970	,	_	_	_	_
37-16	4971-4973	we	person	giv	ana	40-1
37-17	4974-4979	could	_	_	_	_
37-18	4980-4991	demonstrate	_	_	_	_
37-19	4992-4996	that	_	_	_	_
37-20	4997-5000	the	event[273]	giv[273]	coref	40-29[0_273]
37-21	5001-5008	fasting	abstract|event[273]	giv|giv[273]	coref	38-11[286_0]
37-22	5009-5021	intervention	event[273]	giv[273]	_	_
37-23	5022-5025	was	_	_	_	_
37-24	5026-5033	equally	_	_	_	_
37-25	5034-5043	effective	_	_	_	_
37-26	5044-5046	in	_	_	_	_
37-27	5047-5051	T2DM	abstract|person[275]	giv|giv[275]	coref|coref	38-14|38-14
37-28	5052-5060	patients	person[275]	giv[275]	_	_
37-29	5061-5064	and	_	_	_	_
37-30	5065-5067	in	_	_	_	_
37-31	5068-5080	non-diabetic	abstract[276]	new[276]	coref	40-36[308_276]
37-32	5081-5089	subjects	abstract[276]	new[276]	_	_
37-33	5090-5092	in	abstract[276]	new[276]	_	_
37-34	5093-5098	terms	abstract[276]	new[276]	_	_
37-35	5099-5101	of	abstract[276]	new[276]	_	_
37-36	5102-5105	FLI	abstract[276]|abstract	new[276]|giv	coref	40-9
37-37	5106-5107	,	_	_	_	_
37-38	5108-5116	although	_	_	_	_
37-39	5117-5120	the	abstract[278]	new[278]	_	_
37-40	5121-5132	improvement	abstract[278]	new[278]	_	_
37-41	5133-5135	of	abstract[278]	new[278]	_	_
37-42	5136-5141	other	abstract[278]|abstract[279]	new[278]|new[279]	coref	40-22[304_279]
37-43	5142-5152	parameters	abstract[278]|abstract[279]	new[278]|new[279]	_	_
37-44	5153-5154	(	_	_	_	_
37-45	5155-5157	e.	abstract[280]	giv[280]	_	_
37-46	5158-5160	g.	abstract[280]	giv[280]	_	_
37-47	5161-5162	,	abstract[280]	giv[280]	_	_
37-48	5163-5166	HDL	abstract[280]|abstract	giv[280]|new	_	_
37-49	5167-5168	,	abstract[280]	giv[280]	_	_
37-50	5169-5172	LDL	abstract[280]|abstract	giv[280]|new	_	_
37-51	5173-5174	,	abstract[280]	giv[280]	_	_
37-52	5175-5178	and	abstract[280]	giv[280]	_	_
37-53	5179-5181	AP	abstract[280]|abstract	giv[280]|new	_	_
37-54	5182-5183	)	_	_	_	_
37-55	5184-5187	was	_	_	_	_
37-56	5188-5191	not	_	_	_	_
37-57	5192-5194	as	_	_	_	_
37-58	5195-5203	complete	_	_	_	_
37-59	5204-5205	.	_	_	_	_

#Text=These results are in line with a previous study on periodic fasting in T2DM .
38-1	5206-5211	These	abstract[284]	new[284]	coref	40-1[295_284]
38-2	5212-5219	results	abstract[284]	new[284]	_	_
38-3	5220-5223	are	_	_	_	_
38-4	5224-5226	in	_	_	_	_
38-5	5227-5231	line	_	_	_	_
38-6	5232-5236	with	_	_	_	_
38-7	5237-5238	a	abstract[285]	giv[285]	_	_
38-8	5239-5247	previous	abstract[285]	giv[285]	_	_
38-9	5248-5253	study	abstract[285]	giv[285]	_	_
38-10	5254-5256	on	abstract[285]	giv[285]	_	_
38-11	5257-5265	periodic	abstract[285]|abstract[286]	giv[285]|giv[286]	_	_
38-12	5266-5273	fasting	abstract[285]|abstract[286]	giv[285]|giv[286]	_	_
38-13	5274-5276	in	abstract[285]|abstract[286]	giv[285]|giv[286]	_	_
38-14	5277-5281	T2DM	abstract[285]|abstract[286]|event	giv[285]|giv[286]|giv	coref	40-38
38-15	5282-5283	.	_	_	_	_

#Text=Liver enzymes , insulin resistance , and cholesterol levels are related in NAFLD .
39-1	5284-5289	Liver	object|abstract[289]	giv|new[289]	coref|coref|coref|coref	40-13|40-13[301_289]|40-13|40-13[301_289]
39-2	5290-5297	enzymes	abstract[289]	new[289]	_	_
39-3	5298-5299	,	_	_	_	_
39-4	5300-5307	insulin	event|abstract[291]	giv|giv[291]	_	_
39-5	5308-5318	resistance	abstract[291]	giv[291]	_	_
39-6	5319-5320	,	_	_	_	_
39-7	5321-5324	and	_	_	_	_
39-8	5325-5336	cholesterol	abstract[292]	giv[292]	_	_
39-9	5337-5343	levels	abstract[292]	giv[292]	_	_
39-10	5344-5347	are	_	_	_	_
39-11	5348-5355	related	_	_	_	_
39-12	5356-5358	in	_	_	_	_
39-13	5359-5364	NAFLD	substance	giv	_	_
39-14	5365-5366	.	_	_	_	_

#Text=Our results supported a correlation between changes in FLI and changes in liver enzymes ( GGT , and GOT ) and lipid parameters ( TG ) after fasting intervention , although this was limited to subjects without T2DM .
40-1	5367-5370	Our	person|abstract[295]	giv|giv[295]	_	_
40-2	5371-5378	results	abstract[295]	giv[295]	_	_
40-3	5379-5388	supported	_	_	_	_
40-4	5389-5390	a	abstract[296]	new[296]	_	_
40-5	5391-5402	correlation	abstract[296]	new[296]	_	_
40-6	5403-5410	between	abstract[296]	new[296]	_	_
40-7	5411-5418	changes	abstract[296]|abstract[297]	new[296]|new[297]	_	_
40-8	5419-5421	in	abstract[296]|abstract[297]	new[296]|new[297]	_	_
40-9	5422-5425	FLI	abstract[296]|abstract[297]|abstract	new[296]|new[297]|giv	_	_
40-10	5426-5429	and	abstract[296]|abstract[297]	new[296]|new[297]	_	_
40-11	5430-5437	changes	abstract[296]|abstract[297]|abstract	new[296]|new[297]|new	_	_
40-12	5438-5440	in	abstract[296]|abstract[297]	new[296]|new[297]	_	_
40-13	5441-5446	liver	abstract[296]|abstract[297]|object|abstract[301]	new[296]|new[297]|giv|giv[301]	appos|appos	40-16[0_301]|40-16[0_301]
40-14	5447-5454	enzymes	abstract[296]|abstract[297]|abstract[301]	new[296]|new[297]|giv[301]	_	_
40-15	5455-5456	(	_	_	_	_
40-16	5457-5460	GGT	abstract	giv	_	_
40-17	5461-5462	,	_	_	_	_
40-18	5463-5466	and	_	_	_	_
40-19	5467-5470	GOT	_	_	_	_
40-20	5471-5472	)	_	_	_	_
40-21	5473-5476	and	_	_	_	_
40-22	5477-5482	lipid	event|abstract[304]	giv|giv[304]	appos|appos	40-25[0_304]|40-25[0_304]
40-23	5483-5493	parameters	abstract[304]	giv[304]	_	_
40-24	5494-5495	(	_	_	_	_
40-25	5496-5498	TG	abstract	giv	_	_
40-26	5499-5500	)	_	_	_	_
40-27	5501-5506	after	_	_	_	_
40-28	5507-5514	fasting	_	_	_	_
40-29	5515-5527	intervention	event	giv	ana	40-32
40-30	5528-5529	,	_	_	_	_
40-31	5530-5538	although	_	_	_	_
40-32	5539-5543	this	event	giv	_	_
40-33	5544-5547	was	_	_	_	_
40-34	5548-5555	limited	_	_	_	_
40-35	5556-5558	to	_	_	_	_
40-36	5559-5567	subjects	abstract[308]	giv[308]	_	_
40-37	5568-5575	without	abstract[308]	giv[308]	_	_
40-38	5576-5580	T2DM	abstract[308]|abstract	giv[308]|giv	_	_
40-39	5581-5582	.	_	_	_	_
